OptimizeRx Corporation OPRX 深 滬
已收盤 02-06 16:00:00 美东时间
10.89
+0.350
+3.32%
華盛通- 最 高10.95
- 今 開10.76
- 成交量 40.89万股
- 最 低 10.15
- 昨 收 10.54
- 總市值 2.03亿
- 52周最高 22.25
- 市盈率 靜 --
- 換手率 2.19%
- 52周最低 3.9914
- 委 比 18.37%
- 總股本 1864.07万
- 歷史最高 99.178
- 量 比 0.87
- 振 幅 7.59%
- 歷史最低 3.78
- 每 手 1
- 風險率 4.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
OptimizeRx and Experian collaborate to enhance audience measurement and targeting in life sciences marketing. By integrating OptimizeRx's Micro-Neighborhood® data with Experian's identity graph, the partnership aims to improve transparency, accuracy, and scalability for DTC campaigns. This addresses fragmentation in identity resolution, reduces audience loss during onboarding, and provides a more complete view of campaign effectiveness. The solut...
01-07 13:00
OptimizeRx Announced Four New Partner Agreements That Expand Its In-Workflow Point-of-care Network, Fortify Its Long-term Competitive Position, And Increase Total National Provider Identifier Reach, Deal Terms Were Undisclosed
The newly executed agreements include:An exclusive, multi-year agreement with a high-demand e-prescribing (eRx) platform previously available only through a competitive networkA new partnership that extends the Company's
2025-12-17 17:33
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
OptimizeRx Corp. announced four new partner agreements expanding its in-workflow point-of-care (POC) network, boosting National Provider Identifier (NPI) reach by 37%. Key highlights include an exclusive multi-year deal with a high-demand e-prescribing platform, a new partnership extending into the point-of-discharge setting, and renewals with top EHR and eRx partners, one of which is exclusive. These agreements enhance OptimizeRx's market leader...
2025-12-17 09:30
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $17
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $20 to $17.
2025-11-17 20:55
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $24
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $23 to $24.
2025-11-07 22:07
OptimizeRx Raises FY2025 Sales Guidance from $104.000M-$108.000M to $105.000M-$109.000M vs $106.506M Est
OptimizeRx (NASDAQ:OPRX) raises FY2025 sales outlook from $104.000 million-$108.000 million to $105.000 million-$109.000 million vs $106.506 million estimate.
2025-11-07 05:03
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
2025-10-13 11:26
